Category: New products
-
Laser Activation Tested as Potential Cancer Drug Delivery
16 May 2014. Researchers from University at Buffalo in New York developed and tested in the lab a process harnessing lasers to activate drugs inside the body to kill cancer cells. Findings from the proof-of-concept study, led by Buffalo’s Paras Prasad with colleagues from universities in China and Korea, were published online earlier this week…
-
Electronic Circuits Developed That Become Flexible in Body
13 May 2014. Engineers and material scientists from University of Texas in Dallas and University of Tokyo in Japan developed electronic circuits encased in polymers that become flexible and adapt their shape to three-dimensional objects when implanted in mammals. The team from the labs of Walter Voit in Dallas and Takao Someya in Tokyo published…
-
Neurodegenerative Therapies Start-Up Gains $4.8M Seed Funds
12 May 2014. Lysosomal Therapeutics Inc., a start-up developer of therapies for neurodegenerative disorders in Cambridge, Massachusetts, raised $4.8 million in seed financing, the enterprise’s initial operating funds. The company was begun by and is based on the research of Dimitri Krainc, a neurologist at Harvard Medical School and Massachusetts General Hospital in Boston. Atlas…
-
Heart Disease in Lab Recreated with Stem Cells, Chip Device
12 May 2014. Medical and engineering researchers from Harvard University and affiliated hospitals created heart tissue with a genetic disorder on a chip-like device in the lab using stem cells. The results point to a new method for personalized lab testing of therapies for cardiac patients with cells derived from their own tissue, as well…
-
App Measures Health Status with Basic Smartphone Technology
8 May 2014. Computer scientists and medical researchers at University of Illinois in Urbana-Champaign and Chicago designed a mobile app that uses technology already built in today’s smartphones to track basic health indicators. The team led by Illinois computer scientist Bruce Schatz appears in the 10 May 2014 issue of the journal Telemedicine and e-Health.…
-
New Company Formed to Commercialize Synthetic DNA Discovery
7 May 2014. Synthorx Inc., a spin-off company from Scripps Research Institute in La Jolla, California, will commercialize research licensed from Scripps that adds synthetic DNA elements into natural DNA of organisms. The research, led by Scripps chemistry professor and Synthorx co-founder Floyd Romesberg, appears today online in the journal Nature (paid subscription required). Romesberg,…
-
MERS Vaccine Candidate Produces Immune Response in Lab Test
30 April 2014. Researchers at the biotechnology company Novavax Inc. in Gaithersburg, Maryland and University of Maryland medical school in Baltimore found new vaccines made from engineered protein nanoparticles generated in lab mice an immune response to the Middle East Respiratory Syndrome (MERS) and severe acute respiratory syndrome (SARS) viruses. The team led by Maryland…
-
Tablet App Provides Feedback, Improves Drug Adherence
29 April 2014. Computer scientists at Carnegie Mellon University in Pittsburgh designed and tested a tablet app, connected to electronic sensors on a pillbox, that provides feedback to older adults and helps them stick to their medication schedules. Anind Dey, a professor in Carnegie Mellon’s Human-Computer Interaction Institute, and former Ph.D. student Matthew Lee, now…
-
Mayo Clinic Offering Gene Test to Target Chemotherapy
29 April 2014. Mayo Clinic in Rochester, Minnesota now offers cancer patients with solid tumors a test that enables physicians to tailor chemotherapy drugs to the patient’s specific genetic background. The test known as Solid Tumor Targeted Cancer Panel or CANCP is available to patients at the Mayo Clinic and its affiliates worldwide, through the…
-
FDA Approves Intermediate ALS Stem Cell Clinical Trial
28 April 2014. BrainStorm Cell Therapeutics, in New York and Israel, says the U.S. Food and Drug Administration approved its beginning an intermediate stage clinical trial of a stem cell-based therapy for amyotrophic lateral sclerosis or ALS, also known as Lou Gehrig’s disease. The trial will test for safety and tolerability of the company’s treatments…